Phase II Study of Oxaliplatin and Navelbine for Second-Line Treatment of Advanced NSCLC.

Status unconfirmed · Phase 2

Conditions studied: Previously Treated Metastatic Non-Small Cell Lung Cancer

In brief

The purpose of this study is to determine the response rate to treatment with oxaliplatin and Navelbine in patients with previously treated NSCLC. Oxaliplatin and Navelbine have not been clinically evaluated yet. However, Navelbine has been safely administered with other platinum compounds.

Key facts

Study ID

NCT00238849

Run by

Integrated Community Oncology Network

People needed

40

Last updated by the study team

2005-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Locally advanced or metastatic non-small cell lung cancer that has recurred, progressed, or failed to respond to previous systemic chemo.
• Measurable disease
• Good performance status (ECOG 0,1 or 2)

You may not qualify if…

• Previously treated with Oxaliplatin or Navelbine
• Symptomatic CNS metastases

Where it is running

• Integrated Community Oncology Network — Jacksonville, Florida, United States
• Integrated Community Oncology Network — Orange Park, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.